Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

440 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Use of pharmacologic interventions for breast cancer risk reduction: American Society of Clinical Oncology clinical practice guideline.
Visvanathan K, Hurley P, Bantug E, Brown P, Col NF, Cuzick J, Davidson NE, Decensi A, Fabian C, Ford L, Garber J, Katapodi M, Kramer B, Morrow M, Parker B, Runowicz C, Vogel VG 3rd, Wade JL, Lippman SM. Visvanathan K, et al. J Clin Oncol. 2013 Aug 10;31(23):2942-62. doi: 10.1200/JCO.2013.49.3122. Epub 2013 Jul 8. J Clin Oncol. 2013. PMID: 23835710 Review.
Aromatase inhibitors as adjuvant therapy in breast cancer.
Visvanathan K, Davidson NE. Visvanathan K, et al. Oncology (Williston Park). 2003 Mar;17(3):335-42, 347; discussion 347-50, 354. Oncology (Williston Park). 2003. PMID: 12661266 Free article. Review.
New findings about endocrine therapy for breast cancer.
Davidson NE, Visvanathan K, Emens L. Davidson NE, et al. Among authors: visvanathan k. Breast. 2003 Dec;12(6):368-72. doi: 10.1016/s0960-9776(03)00138-3. Breast. 2003. PMID: 14659107 Review.
A phase I vaccine safety and chemotherapy dose-finding trial of an allogeneic GM-CSF-secreting breast cancer vaccine given in a specifically timed sequence with immunomodulatory doses of cyclophosphamide and doxorubicin.
Emens LA, Armstrong D, Biedrzycki B, Davidson N, Davis-Sproul J, Fetting J, Jaffee E, Onners B, Piantadosi S, Reilly RT, Stearns V, Tartakovsky I, Visvanathan K, Wolff A. Emens LA, et al. Among authors: visvanathan k. Hum Gene Ther. 2004 Mar;15(3):313-37. doi: 10.1089/104303404322886165. Hum Gene Ther. 2004. PMID: 15018740 No abstract available.
Preclinical and clinical evaluation of sulforaphane for chemoprevention in the breast.
Cornblatt BS, Ye L, Dinkova-Kostova AT, Erb M, Fahey JW, Singh NK, Chen MS, Stierer T, Garrett-Mayer E, Argani P, Davidson NE, Talalay P, Kensler TW, Visvanathan K. Cornblatt BS, et al. Among authors: visvanathan k. Carcinogenesis. 2007 Jul;28(7):1485-90. doi: 10.1093/carcin/bgm049. Epub 2007 Mar 7. Carcinogenesis. 2007. PMID: 17347138
American society of clinical oncology clinical practice guideline update on the use of pharmacologic interventions including tamoxifen, raloxifene, and aromatase inhibition for breast cancer risk reduction.
Visvanathan K, Chlebowski RT, Hurley P, Col NF, Ropka M, Collyar D, Morrow M, Runowicz C, Pritchard KI, Hagerty K, Arun B, Garber J, Vogel VG, Wade JL, Brown P, Cuzick J, Kramer BS, Lippman SM; American Society of Clinical Oncology. Visvanathan K, et al. J Clin Oncol. 2009 Jul 1;27(19):3235-58. doi: 10.1200/JCO.2008.20.5179. Epub 2009 May 26. J Clin Oncol. 2009. PMID: 19470930 Free PMC article.
440 results